Eli Lilly & Co. raises its sales and revenue outlook again after strong demand for its weight-loss and diabetes medicines, particularly Zepbound, along with Mounjaro. Multiple outlets report that the company’s updated guidance reflects continued momentum in the obesity market, where Lilly remains a leading player.
The coverage also highlights that Lilly is moving beyond injectable treatments, with Business of Fashion noting expansion into pill formulations and work on more powerful weight-loss therapies. Quartz and CNBC emphasize recent performance, including continued sales strength across the latest quarter, while the Financial Times focuses on profit growth alongside demand.
Across outlets, the main difference is emphasis: some lead with the updated financial outlook and guidance timeline (e.g., raised “third time” framing), while others stress market dominance or breadth of the product lineup. A common theme is that Zepbound sales drive the revisions, with Mounjaro also mentioned as part of the demand backdrop.
